Surface Oncology, Inc.
SURF · NASDAQ
6/30/2023 | 3/31/2023 | 12/31/2022 | 9/30/2022 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | 100% | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | -96.9% | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | -71.6% | – |
| EPS Diluted | -0.46 | -0.34 | -0.35 | -0.4 |
| % Growth | -35.3% | 2.9% | 12.5% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |